兰州昊辰咖啡文化传播有限公司

MENU

HISTORY

2019
Plan to establish a new production base at Shandong Province to create an innovative high-end APIs production base with gobal standard.
2018
Acquired the “Suzhou Tianma Pharmaceutical Co.,Ltd.” and established Suzhou production base.
2017
R&D center in nanjing moved to 5,000 square meter newly constructed state-of-the-art building in Nanjing Pukou Economic Development Zone.
2015
The shareholding system was transformed and listed on the New Third Board. Stock code 834804.
2015
Established independent R&D center in Nanjing for the research of new drugs, high-end generic API and intermediates.
2012
Acquired Lanjian Pharmaceutical and established Huai'an Production Base.